Log in

NASDAQ:OSUR - OraSure Technologies Stock Price, Forecast & News

$7.97
+0.23 (+2.97 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$7.75
Now: $7.97
$7.99
50-Day Range
$7.68
MA: $8.23
$8.94
52-Week Range
$6.35
Now: $7.97
$13.25
Volume769,300 shs
Average Volume637,262 shs
Market Capitalization$491.96 million
P/E Ratio15.94
Dividend YieldN/A
Beta1.2
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:OSUR
CUSIP68554V10
Phone610-882-1820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.74 million
Cash Flow$0.60 per share
Book Value$4.62 per share

Profitability

Net Income$20.40 million

Miscellaneous

Employees398
Market Cap$491.96 million
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.


OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings results on Wednesday, November, 6th. The medical instruments supplier reported $0.21 EPS for the quarter, topping the consensus estimate of $0.03 by $0.18. The medical instruments supplier earned $35.99 million during the quarter, compared to analyst estimates of $38.62 million. OraSure Technologies had a net margin of 15.80% and a return on equity of 5.93%. The company's quarterly revenue was down 21.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 earnings per share. View OraSure Technologies' Earnings History.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for OraSure Technologies.

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies issued an update on its FY19 earnings guidance on Wednesday, November, 6th. The company provided earnings per share (EPS) guidance of $0.28-0.31 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.32. The company issued revenue guidance of $150-153 million, compared to the consensus revenue estimate of $162.58 million.

What price target have analysts set for OSUR?

1 analysts have issued 12-month price targets for OraSure Technologies' stock. Their forecasts range from $8.00 to $8.00. On average, they expect OraSure Technologies' stock price to reach $8.00 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for OraSure Technologies.

What is the consensus analysts' recommendation for OraSure Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.

What are Wall Street analysts saying about OraSure Technologies stock?

Here are some recent quotes from research analysts about OraSure Technologies stock:
  • 1. According to Zacks Investment Research, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. " (12/3/2019)
  • 2. Canaccord Genuity analysts commented, "We stick with our HOLD rating and lower our PT from $9 to $7." (8/14/2019)

Has OraSure Technologies been receiving favorable news coverage?

Headlines about OSUR stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OraSure Technologies earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for OraSure Technologies.

Are investors shorting OraSure Technologies?

OraSure Technologies saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 4,150,000 shares, an increase of 8.6% from the October 31st total of 3,820,000 shares. Based on an average trading volume of 647,100 shares, the days-to-cover ratio is currently 6.4 days. Approximately 6.9% of the company's stock are short sold. View OraSure Technologies' Current Options Chain.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the folowing people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
  • Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
  • Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.05%), Systematic Financial Management LP (2.42%), Assenagon Asset Management S.A. (1.16%), Sicart Associates LLC (0.73%), State of New Jersey Common Pension Fund D (0.43%) and Russell Investments Group Ltd. (0.33%). Company insiders that own OraSure Technologies stock include Brian Smith, Charles W Patrick, Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

Which major investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Millennium Management LLC, Assenagon Asset Management S.A., Voloridge Investment Management LLC, SG Americas Securities LLC, Dupont Capital Management Corp and Great West Life Assurance Co. Can. View Insider Buying and Selling for OraSure Technologies.

Which major investors are buying OraSure Technologies stock?

OSUR stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Systematic Financial Management LP, Squarepoint Ops LLC, First Hawaiian Bank, Russell Investments Group Ltd., First Quadrant L P CA, Sicart Associates LLC and Voya Investment Management LLC. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $7.97.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $491.96 million and generates $181.74 million in revenue each year. The medical instruments supplier earns $20.40 million in net income (profit) each year or $0.50 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.View Additional Information About OraSure Technologies.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is http://www.orasure.com/.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]


MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  484 (Vote Outperform)
Underperform Votes:  365 (Vote Underperform)
Total Votes:  849
MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel